Sorbonne Université, INSERM, UMR_S 938, Research Group Cancer, Biology and Therapeutics, Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France.
Thrombosis Center, Tenon-Saint Antoine, Hôpitaux Universitaires de l'Est Parisien, Assistance Publique Hôpitaux de Paris (APHP), France.
Thromb Haemost. 2021 Aug;121(8):992-1007. doi: 10.1055/a-1535-8807. Epub 2021 Jul 20.
One year after the declaration of the coronavirus disease 2019 (COVID-19) pandemic by the World Health Organization (WHO) and despite the implementation of mandatory physical barriers and social distancing, humanity remains challenged by a long-lasting and devastating public health crisis.
Non-pharmacological interventions (NPIs) are efficient mitigation strategies. The success of these NPIs is dependent on the approval and commitment of the population. The launch of a mass vaccination program in many countries in late December 2020 with mRNA vaccines, adenovirus-based vaccines, and inactivated virus vaccines has generated hope for the end of the pandemic.
The continuous appearance of new pathogenic viral strains and the ability of vaccines to prevent infection and transmission raise important concerns as we try to achieve community immunity against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and its variants. The need of a second and even third generation of vaccines has already been acknowledged by the WHO and governments.
There is a critical and urgent need for a balanced and integrated strategy for the management of the COVID-19 outbreaks organized on three axes: (1) revention of the SARS-CoV-2 infection, (2) and early diagnosis of patients at risk of disease worsening, and (3) of medical care (PDA).
The "PDA strategy" integrated into state policy for the support and expansion of health systems and introduction of digital organizations (i.e., telemedicine, e-Health, artificial intelligence, and machine-learning technology) is of major importance for the preservation of citizens' health and life world-wide.
世界卫生组织(WHO)宣布 2019 年冠状病毒病(COVID-19)大流行一年后,尽管实施了强制性的物理障碍和社交距离措施,但人类仍面临持久而严重的公共卫生危机。
非药物干预(NPIs)是有效的缓解策略。这些 NPIs 的成功取决于人口的认可和承诺。2020 年 12 月下旬,许多国家推出了 mRNA 疫苗、腺病毒疫苗和灭活病毒疫苗的大规模疫苗接种计划,为结束大流行带来了希望。
新的致病病毒株不断出现,以及疫苗预防感染和传播的能力,在我们试图针对严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)及其变体获得社区免疫力时,引起了人们的关注。世界卫生组织和各国政府已经认识到需要第二代甚至第三代疫苗。
迫切需要制定一个平衡和综合的 COVID-19 疫情管理策略,该策略组织在三个轴线上:(1)预防 SARS-CoV-2 感染,(2)及早诊断有疾病恶化风险的患者,以及(3)医疗保健(PDA)。
将“PDA 策略”纳入国家政策,以支持和扩大卫生系统,并引入数字组织(即远程医疗、电子医疗、人工智能和机器学习技术),对于维护全球公民的健康和生活至关重要。